

PTPLA Antibody (N-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP13486a

Product Information

Application	WB, IHC-P, E
Primary Accession	<u>B0YJ81</u>
Other Accession	<u>NP_055056.3</u>
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB33378
Calculated MW	32388
Antigen Region	37-66

Additional Information

Protein Information

9200
Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1, 3-hydroxyacyl-CoA dehydratase 1, HACD1, Cementum attachment protein, Protein-tyrosine phosphatase-like member A, PTPLA, HACD1
This PTPLA antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 37-66 amino acids from the N-terminal region of human PTPLA.
WB~~1:1000 IHC-P~~1:100~500 E~~Use at an assay dependent concentration.
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
PTPLA Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

Name	HACD1 {ECO:0000303 PubMed:15164054, ECO:0000312 HGNC:HGNC:9639}
Function	[Isoform 1]: Catalyzes the third of the four reactions of the long-chain fatty acids elongation cycle. This endoplasmic reticulum- bound enzymatic process,

	allows the addition of two carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. This enzyme catalyzes the dehydration of the 3-hydroxyacyl-CoA intermediate into trans-2,3-enoyl-CoA, within each cycle of fatty acid elongation. Thereby, it participates in the production of VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators.
Cellular Location	[Isoform 1]: Endoplasmic reticulum membrane; Multi-pass membrane protein
Tissue Location	Isoform 1 is highly expressed in the myocardium, and to a lesser extent in skeletal and smooth muscular tissues including those from stomach, jejunum, and bladder. Also detected in gingival fibroblasts, periodontal ligament cells, osteoblasts and cementoblasts (PubMed:11054553, PubMed:22067203). Isoform 2 is specifically expressed by cementoblasts but also detected in periodontal ligament cells, heart, liver and kidney (at protein level) (PubMed:22067203).

Background

The protein encoded by this gene contains a characteristic catalytic motif of the protein tyrosine phosphatases (PTPs) family. The PTP motif of this protein has the highly conserved arginine residue replaced by a proline residue; thus it may represent a distinct class of PTPs. Members of the PTP family are known to be signaling molecules that regulate a variety of cellular processes. This gene was preferentially expressed in both adult and fetal heart. A much lower expression level was detected in skeletal and smooth muscle tissues, and no expression was observed in other tissues. The tissue specific expression in the developing and adult heart suggests a role in regulating cardiac development and differentiation.

References

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010) Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009) Liang, X., et al. Hum. Mutat. 30(3):463-471(2009) Lamesch, P., et al. Genomics 89(3):307-315(2007) Grupe, A., et al. Am. J. Hum. Genet. 78(1):78-88(2006)

Images



PTPLA Antibody (N-term) (Cat. #AP13486a) western blot analysis in MDA-MB231 cell line lysates (35ug/lane).This demonstrates the PTPLA antibody detected the PTPLA protein (arrow).

PTPLA Antibody (N-term) (Cat. #AP13486a)immunohistochemistry analysis in formalin fixed and paraffin embedded human heart tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of PTPLA Antibody (N-term) for



immunohistochemistry. Clinical relevance has not been evaluated.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.